Omthera Pharmaceuticals (OMTH -0.7%) says it's submitted a New Drug Application to the FDA seeking approval for the marketing and sale of Epanova for the treatment for patients with severe hypertriglyceridemia. The submission is driven by positive results from two Phase III trials that examined the effectiveness of Epanova in lowering very high triglycerides, and in reducing non-HDL cholesterol in combination with a statin.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs